UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Patient reported outcomes in Friedreich's Ataxia after withdrawal from Idebenone

Cook, A; Boesch, S; Heck, S; Brunt, E; Klockgether, T; Schöls, L; Schulz, A; (2019) Patient reported outcomes in Friedreich's Ataxia after withdrawal from Idebenone. Acta Neurologica Scandinavica , 139 (6) pp. 533-539. 10.1111/ane.13088. Green open access

[img]
Preview
Text
Giunti_Patient reported outcomes in Friedreich's Ataxia after withdrawal from Idebenone_AAM.pdf

Download (330kB) | Preview

Abstract

OBJECTIVES: Friedreich's ataxia is the most common inherited ataxia, and pathogenesis is known to involve mitochondrial oxidative stress. Idebenone is a potent antioxidant which has already been evaluated in several clinical trials in FRDA, with reports of symptomatic benefit but inconclusive objective results. Following patient consultation on design, we have completed a treatment withdrawal study to establish whether patients could correctly determine their treatment allocation to placebo or idebenone. Our aim was to capture subjective experiences of symptoms such as, for example, fatigue, which can be difficult to measure with questionnaires or semi-quantitative scales, particularly in chronic, slowly progressive conditions. MATERIALS AND METHODS: Patients taking idebenone for at least 12 months as part of the open-label MICONOS Extension Study were randomised to receive either placebo or idebenone continuation for two-month treatment cycles. The primary endpoint was patient assessment of treatment assignment. RESULTS: A total of 29 patients were randomised, forming the idebenone group (n=16) and the placebo group (n=13). No significant differences were detected between the idebenone and placebo groups on assessment of treatment assignment or early study withdrawal. A small but significant difference in ataxia rating scale scores was detected between treatment groups when considering ambulatory patients only. CONCLUSIONS: This study provides no data to suggest that FRDA patients could correctly determine their treatment assignment over a 2-month period. We hope that this study design will help inform future trials so that patients' experiences of symptoms are more reliably measured. This article is protected by copyright. All rights reserved.

Type: Article
Title: Patient reported outcomes in Friedreich's Ataxia after withdrawal from Idebenone
Location: Denmark
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/ane.13088
Publisher version: https://doi.org/10.1111/ane.13088
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Friedreich’s ataxia, idebenone, patient reported outcomes
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
URI: https://discovery.ucl.ac.uk/id/eprint/10070972
Downloads since deposit
24Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item